Quest Diagnostics (DGX) Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DGX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View DGX analyst ratings or view top-rated stocks.

10 brokers have issued 12 month target prices for Quest Diagnostics' stock. Their DGX share price forecasts range from $140.00 to $165.00. On average, they anticipate the company's stock price to reach $151.20 in the next year. This suggests a possible upside of 12.9% from the stock's current price.
View analysts price targets for DGX or view top-rated stocks among Wall Street analysts.

Quest Diagnostics' stock was trading at $156.44 at the beginning of the year. Since then, DGX stock has decreased by 14.4% and is now trading at $133.88.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 20th 2023.
View our DGX earnings forecast.

Quest Diagnostics Incorporated (NYSE:DGX) announced its quarterly earnings results on Thursday, April, 27th. The medical research company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.97 by $0.07. The medical research company earned $2.33 billion during the quarter, compared to analysts' expectations of $2.20 billion. Quest Diagnostics had a trailing twelve-month return on equity of 16.51% and a net margin of 8.26%. The business's quarterly revenue was down 10.7% on a year-over-year basis. During the same quarter last year, the business posted $3.22 earnings per share.
Read the conference call transcript.

Quest Diagnostics announced a quarterly dividend on Tuesday, May 16th. Stockholders of record on Tuesday, July 11th will be given a dividend of $0.71 per share on Tuesday, July 25th. This represents a $2.84 annualized dividend and a yield of 2.12%. The ex-dividend date of this dividend is Monday, July 10th.
Read our dividend analysis for DGX.

ETFs with the largest weight of Quest Diagnostics (NYSE:DGX) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF (SMIG), iShares U.S. Healthcare Providers ETF (IHF), First Trust Dorsey Wright Momentum & Low Volatility ETF (DVOL), Davis Select U.S. Equity ETF (DUSA), Nuveen ESG Mid-Cap Value ETF (NUMV), Freedom Day Dividend ETF (MBOX) and Victoryshares Dividend Accelerator ETF (VSDA).

Quest Diagnostics (NYSE:DGX) pays an annual dividend of $2.84 per share and currently has a dividend yield of 2.12%. The company has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 41.89%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DGX will have a dividend payout ratio of 31.21% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DGX.

Quest Diagnostics announced that its Board of Directors has authorized a share buyback plan on Thursday, February 2nd 2023, which authorizes the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 6% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's leadership believes its shares are undervalued.

Quest Diagnostics updated its FY23 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $8.45-8.95 for the period, compared to the consensus EPS estimate of $8.70. The company issued revenue guidance of $8.93-9.08 billion, compared to the consensus revenue estimate of $8.98 billion.

1,053 employees have rated Quest Diagnostics Chief Executive Officer Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Quest Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.66%), State Street Corp (5.07%), Providence Capital Advisors LLC (3.87%), Victory Capital Management Inc. (2.80%), American Century Companies Inc. (2.44%) and Geode Capital Management LLC (2.10%). Insiders that own company stock include Catherine T Doherty, Daniel Stanzione, Gail R Wilensky, Mark Guinan, Michael E Prevoznik, Michael J Deppe, Stephen H Rusckowski, Stephen H Rusckowski and Timothy M Ring.
View institutional ownership trends.

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DGX stock can currently be purchased for approximately $133.88.

Quest Diagnostics (NYSE:DGX) has a market capitalization of $15.00 billion and generates $9.88 billion in revenue each year. The medical research company earns $946 million in net income (profit) each year or $6.78 on an earnings per share basis.

The company employs 49,000 workers across the globe.

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The official website for the company is www.questdiagnostics.com. The medical research company can be reached via phone at (973) 520-2700, via email at investor@questdiagnostics.com, or via fax at 201-462-4169.